[Alpha Biz= Reporter Kim Sangjin] LS Securities expressed optimism about Dong-A ST’s growth prospects for next year, driven by the anticipated launch of its Stelara biosimilar in 2025. On the 4th, LS Securities raised the target price for Dong-A ST by 4.8% to 87,000 KRW, maintaining a “Buy” rating.
Analyst Ji-hoon Shin from LS Securities highlighted, “Stelara, a blockbuster autoimmune disease treatment, achieved 11.3 billion USD in sales in 2023. Dong-A ST’s biosimilar, DMB-3115 (Imuldosa), received FDA approval in the U.S. this past October and a recommendation for approval from the CHMP in Europe."
Shin also noted that the addition of new products, such as Jakyubo, a P-CAB drug for which Dong-A ST collaborates with Jeil Pharma, and Tanamin, a peripheral circulation improvement medication, along with continued growth in Grothropin sales, is expected to drive sustained growth in the ETC division through 2025.
AlphaBIZ Kim SangJin(letyou@alphabiz.co.kr)
